S
Soren Beinke
Researcher at GlaxoSmithKline
Publications - 19
Citations - 3833
Soren Beinke is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: COPD & Bromodomain. The author has an hindex of 8, co-authored 18 publications receiving 3340 citations.
Papers
More filters
Journal ArticleDOI
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme,Kate L. Jeffrey,Uwe Schaefer,Soren Beinke,Scott Dewell,Chun-wa Chung,Rohit Chandwani,Ivan Marazzi,Paul A. Wilson,Hervé Coste,Julia H. White,Jorge Kirilovsky,Charles M. Rice,Jose M. Lora,Rab K. Prinjha,Kevin Lee,Alexander Tarakhovsky +16 more
TL;DR: A synthetic compound (I-BET) is described that by ‘mimicking’ acetylated histones disrupts chromatin complexes responsible for the expression of key inflammatory genes in activated macrophages, and confers protection against lipopolysaccharide-induced endotoxic shock and bacteria-induced sepsis.
Journal ArticleDOI
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson,Rab K. Prinjha,Antje Dittmann,George Giotopoulos,Marcus Bantscheff,Wai-In Chan,Samuel Robson,Chun-wa Chung,Carsten Hopf,Mikhail M. Savitski,Carola Huthmacher,Emma Gudgin,Dave Lugo,Soren Beinke,Trevor D. Chapman,Emma J. Roberts,Peter Ernest Soden,Kurt R. Auger,Olivier Mirguet,Konstanze Doehner,Ruud Delwel,Alan Kenneth Burnett,Phillip Jeffrey,Gerard Drewes,Kevin Lee,Brian J. P. Huntly,Tony Kouzarides +26 more
TL;DR: It is shown that a novel small molecule inhibitor of the BET family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis, establishing the displacement of BET proteins from chromatin as a promising epigenetic therapy for these aggressive leukaemias.
Journal ArticleDOI
Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia
Mark A. Dawson,Rab K. Prinjha,Antje Dittman,George Giotopoulos,Marcus Bantscheff,Wai-In Chan,Samuel Robson,Chun-wa Chung,Carsten Hopf,Mikhail M. Savitski,Konstanze Döhner,Alan Kenneth Burnett,Ruud Delwel,Huthmacher Carola,Emma Gudgin,Dave Lugo,Soren Beinke,Peter Ernest Soden,Kurt R. Auger,Olivier Mirguet,Phillip Jeffrey,Gerard Drewes,Kevin Lee,Tony Kouzarides,Brian J. P. Huntly +24 more
TL;DR: The main phenotypic consequence of BET inhibition in MLL fusion leukaemia is a dramatic early induction of cell cycle arrest and apoptosis and a novel class of potent small molecule inhibitors to the BET family, which is chemically distinct to previously published BET-inhibitors are developed.
Journal ArticleDOI
Identification of a Novel Series of Bet Family Bromodomain Inhibitors: Binding Mode and Profile of I-Bet151 (Gsk1210151A).
Jonathan Thomas Seal,Yann Lamotte,Frédéric Donche,Anne Marie Jeanne Bouillot,Olivier Mirguet,Françoise Gellibert,Edwige Nicodeme,Gael Krysa,Jorge Kirilovsky,Soren Beinke,Scott McCleary,Inma Rioja,Paul Bamborough,Chun-wa Chung,Laurie J. Gordon,Toni Lewis,Ann Louise Walker,Leanne Cutler,Dave Lugo,David Matthew Wilson,Jason Witherington,Kevin Lee,Rab K. Prinjha +22 more
TL;DR: A novel series of quinoline isoxazole BET family bromodomain inhibitors shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine in vivo endotoxaemia model.
Journal ArticleDOI
IFNλ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFNα treatment
Sophia Davidson,Teresa M McCabe,Stefania Crotta,Hans Henrik Gad,Edith M. Hessel,Soren Beinke,Rune Hartmann,Andreas Wack +7 more
TL;DR: IFNλ is proposed as a non‐inflammatory and hence superior treatment option for human IAV infection to limit IAV spread through antiviral gene induction in relevant cells without overstimulating the immune system and driving immunopathology.